{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:29:01Z","timestamp":1793017741367,"version":"4.5.0"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T00:00:00Z","timestamp":1571616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"crossref","award":["2018YFC2000400"],"award-info":[{"award-number":["2018YFC2000400"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81830087"],"award-info":[{"award-number":["81830087"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U1602221"],"award-info":[{"award-number":["U1602221"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31771516"],"award-info":[{"award-number":["31771516"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773149"],"award-info":[{"award-number":["81773149"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00018-019-03339-3","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:49:42Z","timestamp":1571662182000},"page":"1483-1495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The role of E3 ubiquitin ligase HECTD3 in cancer and beyond"],"prefix":"10.1007","volume":"77","author":[{"given":"Qiuyun","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceshi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"key":"3339_CR1","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev.biochem.70.1.503","volume":"70","author":"CM Pickart","year":"2001","unstructured":"Pickart CM (2001) Mechanisms underlying ubiquitination. Annu Rev Biochem 70:503\u2013533","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"3339_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nrm.2017.83","volume":"19","author":"M Rape","year":"2018","unstructured":"Rape M (2018) Ubiquitylation at the crossroads of development and disease. Nat Rev Mol Cell Biol 19(1):59\u201370. \nhttps:\/\/doi.org\/10.1038\/nrm.2017.83","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3339_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","volume":"81","author":"D Komander","year":"2012","unstructured":"Komander D, Rape M (2012) The ubiquitin code. Annu Rev Biochem 81:203\u2013229. \nhttps:\/\/doi.org\/10.1146\/annurev-biochem-060310-170328","journal-title":"Annu Rev Biochem"},{"key":"3339_CR4","doi-asserted-by":"publisher","unstructured":"Tokunaga F, Sakata S-i, Saeki Y, Satomi Y, Kirisako T, Kamei K, Nakagawa T, Kato M, Murata S, Yamaoka S, Yamamoto M, Akira S, Takao T, Tanaka K, Iwai K (2009) Involvement of linear polyubiquitylation of NEMO in NF-\u03baB activation. Nat Cell Biol 11:123. \nhttps:\/\/doi.org\/10.1038\/ncb1821\n\n. \nhttps:\/\/www.nature.com\/articles\/ncb1821#supplementary-information","DOI":"10.1038\/ncb1821"},{"issue":"6","key":"3339_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.sbi.2011.09.009","volume":"21","author":"JF Trempe","year":"2011","unstructured":"Trempe JF (2011) Reading the ubiquitin postal code. Curr Opin Struct Biol 21(6):792\u2013801. \nhttps:\/\/doi.org\/10.1016\/j.sbi.2011.09.009","journal-title":"Curr Opin Struct Biol"},{"issue":"6","key":"3339_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/nrm2690","volume":"10","author":"D Rotin","year":"2009","unstructured":"Rotin D, Kumar S (2009) Physiological functions of the HECT family of ubiquitin ligases. Nat Rev Mol Cell Biol 10(6):398\u2013409. \nhttps:\/\/doi.org\/10.1038\/nrm2690","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"19","key":"3339_CR7","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1038\/sj.emboj.7600808","volume":"24","author":"K Haglund","year":"2005","unstructured":"Haglund K, Dikic I (2005) Ubiquitylation and cell signaling. EMBO J 24(19):3353\u20133359. \nhttps:\/\/doi.org\/10.1038\/sj.emboj.7600808","journal-title":"EMBO J"},{"issue":"10","key":"3339_CR8","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nrc1994","volume":"6","author":"D Hoeller","year":"2006","unstructured":"Hoeller D, Hecker CM, Dikic I (2006) Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 6(10):776\u2013788. \nhttps:\/\/doi.org\/10.1038\/nrc1994","journal-title":"Nat Rev Cancer"},{"issue":"5809","key":"3339_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1126\/science.1127085","volume":"315","author":"D Mukhopadhyay","year":"2007","unstructured":"Mukhopadhyay D, Riezman H (2007) Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science (New York, NY) 315(5809):201\u2013205. \nhttps:\/\/doi.org\/10.1126\/science.1127085","journal-title":"Science (New York, NY)"},{"issue":"2","key":"3339_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/nrm2831","volume":"11","author":"MS Huen","year":"2010","unstructured":"Huen MS, Sy SM, Chen J (2010) BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 11(2):138\u2013148. \nhttps:\/\/doi.org\/10.1038\/nrm2831","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"3339_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrm3143","volume":"12","author":"D Vucic","year":"2011","unstructured":"Vucic D, Dixit VM, Wertz IE (2011) Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12(7):439\u2013452. \nhttps:\/\/doi.org\/10.1038\/nrm3143","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"3339_CR12","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1083\/jcb.201703170","volume":"216","author":"S Gilberto","year":"2017","unstructured":"Gilberto S, Peter M (2017) Dynamic ubiquitin signaling in cell cycle regulation. J Cell Biol 216(8):2259\u20132271. \nhttps:\/\/doi.org\/10.1083\/jcb.201703170","journal-title":"J Cell Biol"},{"issue":"2","key":"3339_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrc.2017.105","volume":"18","author":"D Senft","year":"2018","unstructured":"Senft D, Qi J, Ronai ZA (2018) Ubiquitin ligases in oncogenic transformation and cancer therapy. Nat Rev Cancer 18(2):69\u201388. \nhttps:\/\/doi.org\/10.1038\/nrc.2017.105","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3339_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.3739","volume":"20","author":"D Popovic","year":"2014","unstructured":"Popovic D, Vucic D, Dikic I (2014) Ubiquitination in disease pathogenesis and treatment. Nat Med 20(11):1242\u20131253. \nhttps:\/\/doi.org\/10.1038\/nm.3739","journal-title":"Nat Med"},{"key":"3339_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.pharmthera.2017.03.001","volume":"177","author":"M He","year":"2017","unstructured":"He M, Zhou Z, Wu G, Chen Q, Wan Y (2017) Emerging role of DUBs in tumor metastasis and apoptosis: therapeutic implication. Pharmacol Ther 177:96\u2013107","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3339_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrd.2017.152","volume":"17","author":"JA Harrigan","year":"2018","unstructured":"Harrigan JA, Jacq X, Martin NM, Jackson SP (2018) Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 17(1):57\u201378. \nhttps:\/\/doi.org\/10.1038\/nrd.2017.152","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3339_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.cell.2012.02.065","volume":"149","author":"CH Chan","year":"2012","unstructured":"Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, Huang HY, Tsai KK, Flores LG, Shao Y, Hazle JD, Yu D, Wei W, Sarbassov D, Hung MC, Nakayama KI, Lin HK (2012) The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 149(5):1098\u20131111. \nhttps:\/\/doi.org\/10.1016\/j.cell.2012.02.065","journal-title":"Cell"},{"key":"3339_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.semcdb.2015.02.015","volume":"39","author":"L Dubrez","year":"2015","unstructured":"Dubrez L, Rajalingam K (2015) IAPs and cell migration. Semin Cell Dev Biol 39:124\u2013131. \nhttps:\/\/doi.org\/10.1016\/j.semcdb.2015.02.015","journal-title":"Semin Cell Dev Biol"},{"issue":"9","key":"3339_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.celrep.2015.04.049","volume":"11","author":"H Kim","year":"2015","unstructured":"Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA (2015) Downregulation of the ubiquitin ligase RNF125 underlies resistance of melanoma cells to BRAF inhibitors via JAK1 deregulation. Cell Rep 11(9):1458\u20131473. \nhttps:\/\/doi.org\/10.1016\/j.celrep.2015.04.049","journal-title":"Cell Rep"},{"key":"3339_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.semcancer.2015.09.013","volume":"36","author":"SJ Randle","year":"2016","unstructured":"Randle SJ, Laman H (2016) F-box protein interactions with the hallmark pathways in cancer. Semin Cancer Biol 36:3\u201317. \nhttps:\/\/doi.org\/10.1016\/j.semcancer.2015.09.013","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"3339_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.amjms.2017.12.012","volume":"355","author":"L Yang","year":"2018","unstructured":"Yang L, Chen J, Huang X, Zhang E, He J, Cai Z (2018) Novel insights Into E3 ubiquitin ligase in cancer chemoresistance. Am J Med Sci 355(4):368\u2013376. \nhttps:\/\/doi.org\/10.1016\/j.amjms.2017.12.012","journal-title":"Am J Med Sci"},{"issue":"10","key":"3339_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nrm.2016.91","volume":"17","author":"L Buetow","year":"2016","unstructured":"Buetow L, Huang DT (2016) Structural insights into the catalysis and regulation of E3 ubiquitin ligases. Nat Rev Mol Cell Biol 17(10):626\u2013642. \nhttps:\/\/doi.org\/10.1038\/nrm.2016.91","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"3339_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li Y-C, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13(2):83\u201396. \nhttps:\/\/doi.org\/10.1038\/nrc3430","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3339_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nrc2396","volume":"8","author":"D Frescas","year":"2008","unstructured":"Frescas D, Pagano M (2008) Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 8(6):438\u2013449. \nhttps:\/\/doi.org\/10.1038\/nrc2396","journal-title":"Nat Rev Cancer"},{"key":"3339_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.semcancer.2015.09.005","volume":"36","author":"W Xu","year":"2016","unstructured":"Xu W, Taranets L, Popov N (2016) Regulating Fbw7 on the road to cancer. Semin Cancer Biol 36:62\u201370. \nhttps:\/\/doi.org\/10.1016\/j.semcancer.2015.09.005","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"3339_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15(1):55\u201364. \nhttps:\/\/doi.org\/10.1038\/nrc3844","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"3339_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.tibs.2012.06.007","volume":"37","author":"ML Li","year":"2012","unstructured":"Li ML, Greenberg RA (2012) Links between genome integrity and BRCA1 tumor suppression. Trends Biochem Sci 37(10):418\u2013424. \nhttps:\/\/doi.org\/10.1016\/j.tibs.2012.06.007","journal-title":"Trends Biochem Sci"},{"issue":"20","key":"3339_CR28","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1158\/0008-5472.Can-14-0799","volume":"74","author":"S Wang","year":"2014","unstructured":"Wang S, Sun W, Zhao Y, McEachern D, Meaux I, Barri\u00e8re C, Stuckey JA, Meagher JL, Bai L, Liu L, Hoffman-Luca CG, Lu J, Shangary S, Yu S, Bernard D, Aguilar A, Dos-Santos O, Besret L, Guerif S, Pannier P, Gorge-Bernat D, Debussche L (2014) SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Can Res 74(20):5855\u20135865. \nhttps:\/\/doi.org\/10.1158\/0008-5472.Can-14-0799","journal-title":"Can Res"},{"key":"3339_CR29","doi-asserted-by":"publisher","unstructured":"Aguilar A, Lu J, Liu L, Du D, Bernard D, McEachern D, Przybranowski S, Li X, Luo R, Wen B, Sun D, Wang H, Wen J, Wang G, Zhai Y, Guo M, Yang D, Wang S (2017) Discovery of 4-((3\u2032R,4\u2032S,5\u2032R)-6\u2033-Chloro-4\u2032-(3-chloro-2-fluorophenyl)-1\u2032-ethyl-2\u2033-oxodispiro[cyclohexane-1,2\u2032-pyrrolidine-3\u2032,3\u2033-indoline]-5\u2032-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115\/APG-115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development. J Med Chem 60 (7):2819\u20132839. \nhttps:\/\/doi.org\/10.1021\/acs.jmedchem.6b01665","DOI":"10.1021\/acs.jmedchem.6b01665"},{"issue":"1","key":"3339_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-018-3741-2","volume":"83","author":"WV So","year":"2019","unstructured":"So WV, Ou Yang T-H, Yang X, Zhi J (2019) Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients. Cancer Chemother Pharmacol 83(1):209\u2013213. \nhttps:\/\/doi.org\/10.1007\/s00280-018-3741-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"17","key":"3339_CR31","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1007\/s00018-018-2848-2","volume":"75","author":"J Sluimer","year":"2018","unstructured":"Sluimer J, Distel B (2018) Regulating the human HECT E3 ligases. Cell Mol Life Sci 75(17):3121\u20133141. \nhttps:\/\/doi.org\/10.1007\/s00018-018-2848-2","journal-title":"Cell Mol Life Sci"},{"key":"3339_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","volume":"86","author":"N Zheng","year":"2017","unstructured":"Zheng N, Shabek N (2017) Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem 86:129\u2013157. \nhttps:\/\/doi.org\/10.1146\/annurev-biochem-060815-014922","journal-title":"Annu Rev Biochem"},{"issue":"7349","key":"3339_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nature09966","volume":"474","author":"DM Wenzel","year":"2011","unstructured":"Wenzel DM, Lissounov A, Brzovic PS, Klevit RE (2011) UBCH7 reactivity profile reveals parkin and HHARI to be RING\/HECT hybrids. Nature 474(7349):105\u2013108. \nhttps:\/\/doi.org\/10.1038\/nature09966","journal-title":"Nature"},{"issue":"2","key":"3339_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1515\/hsz-2017-0184","volume":"399","author":"S Lorenz","year":"2018","unstructured":"Lorenz S (2018) Structural mechanisms of HECT-type ubiquitin ligases. Biol Chem 399(2):127\u2013145. \nhttps:\/\/doi.org\/10.1515\/hsz-2017-0184","journal-title":"Biol Chem"},{"issue":"6509","key":"3339_CR35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/373081a0","volume":"373","author":"M Scheffner","year":"1995","unstructured":"Scheffner M, Nuber U, Huibregtse JM (1995) Protein ubiquitination involving an E1\u2013E2\u2013E3 enzyme ubiquitin thioester cascade. Nature 373(6509):81\u201383","journal-title":"Nature"},{"issue":"5443","key":"3339_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1126\/science.286.5443.1321","volume":"286","author":"L Huang","year":"1999","unstructured":"Huang L, Kinnucan E, Wang G, Beaudenon S, Howley PM, Huibregtse JM, Pavletich NP (1999) Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science (New York, NY) 286(5443):1321\u20131326","journal-title":"Science (New York, NY)"},{"issue":"11","key":"3339_CR37","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1073\/pnas.92.11.5249-a","volume":"92","author":"JM Huibregtse","year":"1995","unstructured":"Huibregtse JM, Scheffner M, Beaudenon S, Howley PM (1995) A family of proteins structurally and functionally related to the E6-AP ubiquitin-protein ligase. Proc Natl Acad Sci USA 92(11):5249","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3339_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(93)90384-3","volume":"75","author":"M Scheffner","year":"1993","unstructured":"Scheffner M, Huibregtse JM, Vierstra RD, Howley PM (1993) The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3):495\u2013505","journal-title":"Cell"},{"issue":"8","key":"3339_CR39","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/cdd.2009.31","volume":"16","author":"I Louria-Hayon","year":"2009","unstructured":"Louria-Hayon I, Alsheich-Bartok O, Levav-Cohen Y, Silberman I, Berger M, Grossman T, Matentzoglu K, Jiang YH, Muller S, Scheffner M, Haupt S, Haupt Y (2009) E6AP promotes the degradation of the PML tumor suppressor. Cell Death Differ 16(8):1156\u20131166. \nhttps:\/\/doi.org\/10.1038\/cdd.2009.31","journal-title":"Cell Death Differ"},{"issue":"4","key":"3339_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2011-10-387647","volume":"120","author":"K Wolyniec","year":"2012","unstructured":"Wolyniec K, Shortt J, de Stanchina E, Levav-Cohen Y, Alsheich-Bartok O, Louria-Hayon I, Corneille V, Kumar B, Woods SJ, Opat S, Johnstone RW, Scott CL, Segal D, Pandolfi PP, Fox S, Strasser A, Jiang YH, Lowe SW, Haupt S, Haupt Y (2012) E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood 120(4):822\u2013832. \nhttps:\/\/doi.org\/10.1182\/blood-2011-10-387647","journal-title":"Blood"},{"issue":"48","key":"3339_CR41","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1038\/onc.2016.159","volume":"35","author":"PJ Paul","year":"2016","unstructured":"Paul PJ, Raghu D, Chan AL, Gulati T, Lambeth L, Takano E, Herold MJ, Hagekyriakou J, Vessella RL, Fedele C, Shackleton M, Williams ED, Fox S, Williams S, Haupt S, Gamell C, Haupt Y (2016) Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. Oncogene 35(48):6235\u20136245. \nhttps:\/\/doi.org\/10.1038\/onc.2016.159","journal-title":"Oncogene"},{"issue":"14","key":"3339_CR42","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/0008-5472.Can-15-1553","volume":"76","author":"M Mansour","year":"2016","unstructured":"Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y (2016) The E3-ligase E6AP represses breast cancer metastasis via regulation of ECT2-Rho signaling. Can Res 76(14):4236\u20134248. \nhttps:\/\/doi.org\/10.1158\/0008-5472.Can-15-1553","journal-title":"Can Res"},{"issue":"16","key":"3339_CR43","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/sj.onc.1210021","volume":"26","author":"C Chen","year":"2007","unstructured":"Chen C, Sun X, Guo P, Dong XY, Sethi P, Zhou W, Zhou Z, Petros J, Frierson HF, Vessella RL, Atfi A, Dong JT (2007) Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 26(16):2386\u20132394","journal-title":"Oncogene"},{"issue":"1","key":"3339_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ijc.22653","volume":"121","author":"C Chen","year":"2007","unstructured":"Chen C, Zhou Z, Ross JS, Zhou W, Dong JT (2007) The amplified WWP1 gene is a potential molecular target in breast cancer. Int J Cancer 121(1):80\u201387","journal-title":"Int J Cancer"},{"issue":"12","key":"3339_CR45","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/cdd.2008.134","volume":"15","author":"Y Li","year":"2008","unstructured":"Li Y, Zhou Z, Chen C (2008) WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ 15(12):1941\u20131951. \nhttps:\/\/doi.org\/10.1038\/cdd.2008.134","journal-title":"Cell Death Differ"},{"issue":"50","key":"3339_CR46","doi-asserted-by":"publisher","first-page":"41553","DOI":"10.1074\/jbc.M506183200","volume":"280","author":"C Chen","year":"2005","unstructured":"Chen C, Sun X, Guo P, Dong XY, Sethi P, Cheng X, Zhou J, Ling J, Simons JW, Lingrel JB, Dong JT (2005) Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J Biol Chem 280(50):41553\u201341561","journal-title":"J Biol Chem"},{"issue":"41","key":"3339_CR47","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1038\/sj.onc.1207885","volume":"23","author":"A Komuro","year":"2004","unstructured":"Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K (2004) Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene 23(41):6914\u20136923. \nhttps:\/\/doi.org\/10.1038\/sj.onc.1207885","journal-title":"Oncogene"},{"issue":"33","key":"3339_CR48","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1038\/onc.2009.162","volume":"28","author":"Y Li","year":"2009","unstructured":"Li Y, Zhou Z, Alimandi M, Chen C (2009) WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 28(33):2948\u20132958. \nhttps:\/\/doi.org\/10.1038\/onc.2009.162","journal-title":"Oncogene"},{"issue":"5","key":"3339_CR49","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1158\/0008-5472.Can-10-3516","volume":"71","author":"Z Salah","year":"2011","unstructured":"Salah Z, Melino G, Aqeilan RI (2011) Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Can Res 71(5):2010\u20132020. \nhttps:\/\/doi.org\/10.1158\/0008-5472.Can-10-3516","journal-title":"Can Res"},{"key":"3339_CR50","doi-asserted-by":"publisher","unstructured":"Chang L, Shen L, Zhou H, Gao J, Pan H, Zheng L, Armstrong B, Peng Y, Peng G, Zhou BP, Rosen ST, Shen B (2019) ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response. Nucleic Acids Res 47(2):824\u2013842. \nhttps:\/\/doi.org\/10.1093\/nar\/gky1199","DOI":"10.1093\/nar\/gky1199"},{"issue":"47","key":"3339_CR51","doi-asserted-by":"publisher","first-page":"36818","DOI":"10.1074\/jbc.C000580200","volume":"275","author":"X Lin","year":"2000","unstructured":"Lin X, Liang M, Feng XH (2000) Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275(47):36818\u201336822","journal-title":"J Biol Chem"},{"issue":"23","key":"3339_CR52","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1038\/emboj.2011.393","volume":"30","author":"LY Tang","year":"2011","unstructured":"Tang LY, Yamashita M, Coussens NP, Tang Y, Wang XC, Li CL, Deng CX, Cheng SY, Zhang YE (2011) Ablation of Smurf2 reveals an inhibition in TGF-beta signalling through multiple mono-ubiquitination of Smad3. EMBO J 30(23):4777\u20134789. \nhttps:\/\/doi.org\/10.1038\/emboj.2011.393","journal-title":"EMBO J"},{"issue":"2","key":"3339_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nm.2596","volume":"18","author":"M Blank","year":"2012","unstructured":"Blank M, Tang Y, Yamashita M, Burkett SS, Cheng SY, Zhang YE (2012) A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat Med 18(2):227\u2013234. \nhttps:\/\/doi.org\/10.1038\/nm.2596","journal-title":"Nat Med"},{"issue":"1","key":"3339_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cell.2006.11.039","volume":"128","author":"X Wang","year":"2007","unstructured":"Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP, Jiang X (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128(1):129\u2013139","journal-title":"Cell"},{"issue":"6","key":"3339_CR55","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/ncb2240","volume":"13","author":"S Maddika","year":"2011","unstructured":"Maddika S, Kavela S, Rani N, Palicharla VR, Pokorny JL, Sarkaria JN, Chen J (2011) WWP2 is an E3 ubiquitin ligase for PTEN. Nat Cell Biol 13(6):728\u2013733. \nhttps:\/\/doi.org\/10.1038\/ncb2240","journal-title":"Nat Cell Biol"},{"issue":"4","key":"3339_CR56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.bbrc.2008.01.022","volume":"367","author":"J Yu","year":"2008","unstructured":"Yu J, Lan J, Zhu Y, Li X, Lai X, Xue Y, Jin C, Huang H (2008) The E3 ubiquitin ligase HECTD3 regulates ubiquitination and degradation of Tara. Biochem Biophys Res Commun 367(4):805\u2013812. \nhttps:\/\/doi.org\/10.1016\/j.bbrc.2008.01.022","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"3339_CR57","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10571-008-9303-0","volume":"29","author":"L Zhang","year":"2009","unstructured":"Zhang L, Kang L, Bond W, Zhang N (2009) Interaction between syntaxin 8 and HECTd3, a HECT domain ligase. Cell Mol Neurobiol 29(1):115\u2013121. \nhttps:\/\/doi.org\/10.1007\/s10571-008-9303-0","journal-title":"Cell Mol Neurobiol"},{"key":"3339_CR58","doi-asserted-by":"publisher","unstructured":"Li Y, Chen X, Wang Z, Zhao D, Chen H, Chen W, Zhou Z, Zhang J, Zhang J, Li H, Chen C (2013) The HECTD3 E3 ubiquitin ligase suppresses cisplatin-induced apoptosis via stabilizing MALT1. Neoplasia 15(1):39-IN15. \nhttps:\/\/doi.org\/10.1593\/neo.121362","DOI":"10.1593\/neo.121362"},{"issue":"1","key":"3339_CR59","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41467-019-08605-3","volume":"10","author":"JJ Cho","year":"2019","unstructured":"Cho JJ, Xu Z, Parthasarathy U, Drashansky TT, Helm EY, Zuniga AN, Lorentsen KJ, Mansouri S, Cho JY, Edelmann MJ, Duong DM, Gehring T, Seeholzer T, Krappmann D, Uddin MN, Califano D, Wang RL, Jin L, Li H, Lv D, Zhou D, Zhou L, Avram D (2019) Hectd3 promotes pathogenic Th17 lineage through Stat3 activation and Malt1 signaling in neuroinflammation. Nat Commun 10(1):701. \nhttps:\/\/doi.org\/10.1038\/s41467-019-08605-3","journal-title":"Nat Commun"},{"key":"3339_CR60","doi-asserted-by":"publisher","first-page":"e935","DOI":"10.1038\/cddis.2013.464","volume":"4","author":"Y Li","year":"2013","unstructured":"Li Y, Kong Y, Zhou Z, Chen H, Wang Z, Hsieh YC, Zhao D, Zhi X, Huang J, Zhang J, Li H, Chen C (2013) The HECTD3 E3 ubiquitin ligase facilitates cancer cell survival by promoting K63-linked polyubiquitination of caspase-8. Cell Death Dis 4:e935. \nhttps:\/\/doi.org\/10.1038\/cddis.2013.464","journal-title":"Cell Death Dis"},{"key":"3339_CR61","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2017.07.004","volume":"404","author":"Y Li","year":"2017","unstructured":"Li Y, Wu X, Li L, Liu Y, Xu C, Su D, Liu Z (2017) The E3 ligase HECTD3 promotes esophageal squamous cell carcinoma (ESCC) growth and cell survival through targeting and inhibiting caspase-9 activation. Cancer Lett 404:44\u201352. \nhttps:\/\/doi.org\/10.1016\/j.canlet.2017.07.004","journal-title":"Cancer Lett"},{"issue":"12","key":"3339_CR62","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1016\/j.celrep.2017.05.078","volume":"19","author":"Z Li","year":"2017","unstructured":"Li Z, Zhou L, Prodromou C, Savic V, Pearl LH (2017) HECTD3 mediates an HSP90-dependent degradation pathway for protein kinase clients. Cell Rep 19(12):2515\u20132528. \nhttps:\/\/doi.org\/10.1016\/j.celrep.2017.05.078","journal-title":"Cell Rep"},{"issue":"9","key":"3339_CR63","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1172\/JCI120406","volume":"128","author":"F Li","year":"2018","unstructured":"Li F, Li Y, Liang H, Xu T, Kong Y, Huang M, Xiao J, Chen X, Xia H, Wu Y, Zhou Z, Guo X, Hu C, Yang C, Cheng X, Chen C, Qi X (2018) HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection. J Clin Invest 128(9):4148\u20134162. \nhttps:\/\/doi.org\/10.1172\/JCI120406","journal-title":"J Clin Invest"},{"issue":"22","key":"3339_CR64","doi-asserted-by":"publisher","first-page":"4634","DOI":"10.1038\/sj.emboj.7601897","volume":"26","author":"A Oeckinghaus","year":"2007","unstructured":"Oeckinghaus A, Wegener E, Welteke V, Ferch U, Arslan SC, Ruland J, Scheidereit C, Krappmann D (2007) Malt1 ubiquitination triggers NF-kappaB signaling upon T-cell activation. EMBO J 26(22):4634\u20134645","journal-title":"EMBO J"},{"key":"3339_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32239","author":"Y Kong","year":"2019","unstructured":"Kong Y, Wang Z, Huang M, Zhou Z, Li Y, Miao H, Wan X, Huang J, Mao X, Chen C (2019) CUL7 promotes cancer cell survival through promoting Caspase-8 ubiquitination. Int J Cancer. \nhttps:\/\/doi.org\/10.1002\/ijc.32239","journal-title":"Int J Cancer"},{"key":"3339_CR66","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2017.09.048","volume":"411","author":"T Shu","year":"2017","unstructured":"Shu T, Li Y, Wu X, Li B, Liu Z (2017) Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment. Cancer Lett 411:65\u201373. \nhttps:\/\/doi.org\/10.1016\/j.canlet.2017.09.048","journal-title":"Cancer Lett"},{"issue":"2","key":"3339_CR67","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc1275","volume":"4","author":"H Yu","year":"2004","unstructured":"Yu H, Jove R (2004) The STATs of cancer\u2014new molecular targets come of age. Nat Rev Cancer 4(2):97\u2013105. \nhttps:\/\/doi.org\/10.1038\/nrc1275","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3339_CR68","first-page":"1563","volume":"6","author":"X Wu","year":"2016","unstructured":"Wu X, Li L, Li Y, Liu Z (2016) MiR-153 promotes breast cancer cell apoptosis by targeting HECTD3. Am J Cancer Res 6(7):1563\u20131571","journal-title":"Am J Cancer Res"},{"issue":"4","key":"3339_CR69","doi-asserted-by":"publisher","first-page":"533","DOI":"10.7150\/thno.14315","volume":"6","author":"R Liu","year":"2016","unstructured":"Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, Chen H, Dong C, Yang R, Liu S, Chen C (2016) Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression. Theranostics 6(4):533\u2013544. \nhttps:\/\/doi.org\/10.7150\/thno.14315","journal-title":"Theranostics"},{"issue":"15","key":"3339_CR70","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1038\/s41388-017-0089-8","volume":"37","author":"H Liang","year":"2018","unstructured":"Liang H, Xiao J, Zhou Z, Wu J, Ge F, Li Z, Zhang H, Sun J, Li F, Liu R, Chen C (2018) Hypoxia induces miR-153 through the IRE1alpha-XBP1 pathway to fine tune the HIF1alpha\/VEGFA axis in breast cancer angiogenesis. Oncogene 37(15):1961\u20131975. \nhttps:\/\/doi.org\/10.1038\/s41388-017-0089-8","journal-title":"Oncogene"},{"issue":"4","key":"3339_CR71","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10456-018-9630-9","volume":"21","author":"H Liang","year":"2018","unstructured":"Liang H, Ge F, Xu Y, Xiao J, Zhou Z, Liu R, Chen C (2018) miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells. Angiogenesis 21(4):849\u2013860. \nhttps:\/\/doi.org\/10.1007\/s10456-018-9630-9","journal-title":"Angiogenesis"},{"issue":"5","key":"3339_CR72","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/0008-5472.Can-17-1089","volume":"78","author":"P Ekambaram","year":"2018","unstructured":"Ekambaram P, Lee JL, Hubel NE, Hu D, Yerneni S, Campbell PG, Pollock N, Klei LR, Concel VJ, Delekta PC, Chinnaiyan AM, Tomlins SA, Rhodes DR, Priedigkeit N, Lee AV, Oesterreich S, McAllister-Lucas LM, Lucas PC (2018) The CARMA3-Bcl10-MALT1 signalosome drives NF\u03baB activation and promotes aggressiveness in angiotensin II receptor-positive breast cancer. Can Res 78(5):1225\u20131240. \nhttps:\/\/doi.org\/10.1158\/0008-5472.Can-17-1089","journal-title":"Can Res"},{"key":"3339_CR73","doi-asserted-by":"publisher","unstructured":"Cheng L, Deng N, Yang N, Zhao X, Lin X (2019) Malt1 protease is critical in maintaining function of regulatory T cells and may be a therapeutic target for antitumor immunity. J Immunol (Baltimore, Md: 1950) 202(10):3008\u20133019. \nhttps:\/\/doi.org\/10.4049\/jimmunol.1801614","DOI":"10.4049\/jimmunol.1801614"},{"issue":"3","key":"3339_CR74","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.molcel.2008.06.008","volume":"31","author":"H Kawadler","year":"2008","unstructured":"Kawadler H, Gantz MA, Riley JL, Yang X (2008) The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation. Mol Cell 31(3):415\u2013421. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2008.06.008","journal-title":"Mol Cell"},{"issue":"12","key":"3339_CR75","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.1172\/jci63528","volume":"122","author":"A Br\u00fcstle","year":"2012","unstructured":"Br\u00fcstle A, Brenner D, Knobbe CB, Lang PA, Virtanen C, Hershenfield BM, Reardon C, Lacher SM, Ruland J, Ohashi PS, Mak TW (2012) The NF-\u03baB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J Clin Invest 122(12):4698\u20134709. \nhttps:\/\/doi.org\/10.1172\/jci63528","journal-title":"J Clin Invest"},{"issue":"8","key":"3339_CR76","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrd1159","volume":"2","author":"A Paramore","year":"2003","unstructured":"Paramore A, Frantz S (2003) Bortezomib. Nat Rev Drug Discov 2(8):611\u2013612","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3339_CR77","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","volume":"5","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5(5):417\u2013421. \nhttps:\/\/doi.org\/10.1016\/S1535-6108(04)00120-5","journal-title":"Cancer Cell"},{"key":"3339_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.09.001","volume":"23","author":"J Qi","year":"2015","unstructured":"Qi J, Ronai ZA (2015) Dysregulation of ubiquitin ligases in cancer. Drug Resist Updat 23:1\u201311. \nhttps:\/\/doi.org\/10.1016\/j.drup.2015.09.001","journal-title":"Drug Resist Updat"},{"issue":"12","key":"3339_CR79","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/nm1146","volume":"10","author":"N Issaeva","year":"2004","unstructured":"Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LGGC, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53\u2013HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321\u20131328. \nhttps:\/\/doi.org\/10.1038\/nm1146","journal-title":"Nat Med"},{"issue":"5659","key":"3339_CR80","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, NY) 303(5659):844\u2013848","journal-title":"Science (New York, NY)"},{"issue":"6","key":"3339_CR81","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2005.04.029","volume":"7","author":"Y Yang","year":"2005","unstructured":"Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, Safiran YJ, Oberoi P, Kenten JH, Phillips AC, Weissman AM, Vousden KH (2005) Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7(6):547\u2013559","journal-title":"Cancer Cell"},{"issue":"11","key":"3339_CR82","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/s1470-2045(12)70474-6","volume":"13","author":"I Ray-Coquard","year":"2012","unstructured":"Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN (2012) Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 13(11):1133\u20131140. \nhttps:\/\/doi.org\/10.1016\/s1470-2045(12)70474-6","journal-title":"Lancet Oncol"},{"issue":"10","key":"3339_CR83","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1073\/pnas.0708917105","volume":"105","author":"S Shangary","year":"2008","unstructured":"Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J, Bernard D, Zhang J, Lu Y, Gu Q, Shah RB, Pienta KJ, Ling X, Kang S, Guo M, Sun Y, Yang D, Wang S (2008) Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 105(10):3933\u20133938. \nhttps:\/\/doi.org\/10.1073\/pnas.0708917105","journal-title":"Proc Natl Acad Sci USA"},{"key":"3339_CR84","doi-asserted-by":"publisher","unstructured":"Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM (2010) MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer (Oxford, England: 1990) 46(6):1122\u20131131. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2010.01.015","DOI":"10.1016\/j.ejca.2010.01.015"},{"issue":"19","key":"3339_CR85","doi-asserted-by":"publisher","first-page":"7223","DOI":"10.1021\/ja3125417","volume":"135","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Liu L, Sun W, Lu J, McEachern D, Li X, Yu S, Bernard D, Ochsenbein P, Ferey V, Carry JC, Deschamps JR, Sun D, Wang S (2013) Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc 135(19):7223\u20137234. \nhttps:\/\/doi.org\/10.1021\/ja3125417","journal-title":"J Am Chem Soc"},{"issue":"13","key":"3339_CR86","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1021\/jm4005708","volume":"56","author":"Y Zhao","year":"2013","unstructured":"Zhao Y, Yu S, Sun W, Liu L, Lu J, McEachern D, Shargary S, Bernard D, Li X, Zhao T, Zou P, Sun D, Wang S (2013) A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 56(13):5553\u20135561. \nhttps:\/\/doi.org\/10.1021\/jm4005708","journal-title":"J Med Chem"},{"issue":"12","key":"3339_CR87","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1158\/1535-7163.MCT-16-0028","volume":"15","author":"J Lu","year":"2016","unstructured":"Lu J, McEachern D, Li S, Ellis MJ, Wang S (2016) Reactivation of p53 by MDM2 Inhibitor MI-77301 for the treatment of endocrine-resistant breast cancer. Mol Cancer Ther 15(12):2887\u20132893","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"3339_CR88","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/1078-0432.Ccr-16-1235","volume":"23","author":"F N\u00f6r","year":"2017","unstructured":"N\u00f6r F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, Helman JI, Sant\u2019Ana Filho M, Wang S, N\u00f6r JE (2017) Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res 23(4):1036\u20131048. \nhttps:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-1235","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3339_CR89","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1158\/1078-0432.Ccr-17-2730","volume":"25","author":"A Andrews","year":"2019","unstructured":"Andrews A, Warner K, Rodriguez-Ramirez C, Pearson AT, N\u00f6r F, Zhang Z, Kerk S, Kulkarni A, Helman JI, Brenner JC, Wicha MS, Wang S, N\u00f6r JE (2019) Ablation of cancer stem cells by therapeutic inhibition of the MDM2-p53 interaction in mucoepidermoid carcinoma. Clin Cancer Res 25(5):1588\u20131600. \nhttps:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-2730","journal-title":"Clin Cancer Res"},{"issue":"14","key":"3339_CR90","doi-asserted-by":"publisher","first-page":"5979","DOI":"10.1021\/jm400487c","volume":"56","author":"Q Ding","year":"2013","unstructured":"Ding Q, Zhang Z, Liu JJ, Jiang N, Zhang J, Ross TM, Chu XJ, Bartkovitz D, Podlaski F, Janson C, Tovar C, Filipovic ZM, Higgins B, Glenn K, Packman K, Vassilev LT, Graves B (2013) Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development. J Med Chem 56(14):5979\u20135983. \nhttps:\/\/doi.org\/10.1021\/jm400487c","journal-title":"J Med Chem"},{"issue":"1","key":"3339_CR91","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.molcel.2016.02.005","volume":"62","author":"W Zhang","year":"2016","unstructured":"Zhang W, Wu KP, Sartori MA, Kamadurai HB, Ordureau A, Jiang C, Mercredi PY, Murchie R, Hu J, Persaud A, Mukherjee M, Li N, Doye A, Walker JR, Sheng Y, Hao Z, Li Y, Brown KR, Lemichez E, Chen J, Tong Y, Harper JW, Moffat J, Rotin D, Schulman BA, Sidhu SS (2016) System-wide modulation of HECT E3 ligases with selective ubiquitin variant probes. Mol Cell 62(1):121\u2013136. \nhttps:\/\/doi.org\/10.1016\/j.molcel.2016.02.005","journal-title":"Mol Cell"},{"issue":"13","key":"3339_CR92","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1073\/pnas.1519389113","volume":"113","author":"M Gorelik","year":"2016","unstructured":"Gorelik M, Orlicky S, Sartori MA, Tang X, Marcon E, Kurinov I, Greenblatt JF, Tyers M, Moffat J, Sicheri F, Sidhu SS (2016) Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1\u2013F-box interface. Proc Natl Acad Sci 113(13):3527. \nhttps:\/\/doi.org\/10.1073\/pnas.1519389113","journal-title":"Proc Natl Acad Sci"},{"issue":"2","key":"3339_CR93","doi-asserted-by":"publisher","first-page":"456.e410","DOI":"10.1016\/j.molcel.2017.09.027","volume":"68","author":"M Gabrielsen","year":"2017","unstructured":"Gabrielsen M, Buetow L, Nakasone MA, Ahmed SF, Sibbet GJ, Smith BO, Zhang W, Sidhu SS, Huang DT (2017) A general strategy for discovery of inhibitors and activators of RING and U-box E3 ligases with ubiquitin variants. Mol Cell 68(2):456.e410\u2013470.e410","journal-title":"Mol Cell"},{"issue":"47","key":"3339_CR94","doi-asserted-by":"publisher","first-page":"16736","DOI":"10.1073\/pnas.1412152111","volume":"111","author":"T Mund","year":"2014","unstructured":"Mund T, Lewis MJ, Maslen S, Pelham HR (2014) Peptide and small molecule inhibitors of HECT-type ubiquitin ligases. Proc Natl Acad Sci USA 111(47):16736\u201316741. \nhttps:\/\/doi.org\/10.1073\/pnas.1412152111","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3339_CR95","doi-asserted-by":"publisher","first-page":"e1203","DOI":"10.1038\/cddis.2014.113","volume":"5","author":"M Rossi","year":"2014","unstructured":"Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, Bernassola F, Cavasotto CN, Knight RA, Ciechanover A, Melino G (2014) High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis 5(5):e1203. \nhttps:\/\/doi.org\/10.1038\/cddis.2014.113","journal-title":"Cell Death Dis"},{"issue":"39","key":"3339_CR96","doi-asserted-by":"publisher","first-page":"12442","DOI":"10.1021\/jacs.5b06839","volume":"137","author":"SG Kathman","year":"2015","unstructured":"Kathman SG, Span I, Smith AT, Xu Z, Zhan J, Rosenzweig AC, Statsyuk AV (2015) A small molecule that switches a ubiquitin ligase from a processive to a distributive enzymatic mechanism. J Am Chem Soc 137(39):12442\u201312445. \nhttps:\/\/doi.org\/10.1021\/jacs.5b06839","journal-title":"J Am Chem Soc"},{"key":"3339_CR97","doi-asserted-by":"publisher","unstructured":"Sander B, Xu W, Eilers M, Popov N, Lorenz S (2017) A conformational switch regulates the ubiquitin ligase HUWE1. eLife 6. \nhttps:\/\/doi.org\/10.7554\/elife.21036","DOI":"10.7554\/elife.21036"},{"issue":"3","key":"3339_CR98","doi-asserted-by":"publisher","first-page":"345.e346","DOI":"10.1016\/j.molcel.2017.03.020","volume":"66","author":"Z Chen","year":"2017","unstructured":"Chen Z, Jiang H, Xu W, Li X, Dempsey DR, Zhang X, Devreotes P, Wolberger C, Amzel LM, Gabelli SB, Cole PA (2017) A tunable brake for HECT ubiquitin ligases. Mol Cell 66(3):345.e346\u2013357.e346","journal-title":"Mol Cell"},{"issue":"18","key":"3339_CR99","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1021\/bi301710c","volume":"52","author":"AL Chan","year":"2013","unstructured":"Chan AL, Grossman T, Zuckerman V, Campigli Di Giammartino D, Moshel O, Scheffner M, Monahan B, Pilling P, Jiang YH, Haupt S, Schueler-Furman O, Haupt Y (2013) c-Abl phosphorylates E6AP and regulates its E3 ubiquitin ligase activity. Biochemistry 52(18):3119\u20133129. \nhttps:\/\/doi.org\/10.1021\/bi301710c","journal-title":"Biochemistry"},{"issue":"23\u201324","key":"3339_CR100","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.drudis.2013.09.001","volume":"18","author":"M Hamzeh-Mivehroud","year":"2013","unstructured":"Hamzeh-Mivehroud M, Alizadeh AA, Morris MB, Church WB, Dastmalchi S (2013) Phage display as a technology delivering on the promise of peptide drug discovery. Drug Discov Today 18(23\u201324):1144\u20131157. \nhttps:\/\/doi.org\/10.1016\/j.drudis.2013.09.001","journal-title":"Drug Discov Today"},{"issue":"8","key":"3339_CR101","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/1087057113485789","volume":"18","author":"D Ungermannova","year":"2013","unstructured":"Ungermannova D, Lee J, Zhang G, Dallmann HG, McHenry CS, Liu X (2013) High-throughput screening alphascreen assay for identification of small-molecule inhibitors of ubiquitin E3 Ligase SCFSkp2-Cks1. J Biomol Screen 18(8):910\u2013920. \nhttps:\/\/doi.org\/10.1177\/1087057113485789","journal-title":"J Biomol Screen"},{"issue":"9","key":"3339_CR102","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrd.2016.109","volume":"15","author":"DA Erlanson","year":"2016","unstructured":"Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H (2016) Twenty years on: the impact of fragments on drug discovery. Nat Rev Drug Discov 15(9):605\u2013619. \nhttps:\/\/doi.org\/10.1038\/nrd.2016.109","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3339_CR103","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2016.08.015","volume":"30","author":"L Gu","year":"2016","unstructured":"Gu L, Zhang H, Liu T, Zhou S, Du Y, Xiong J, Yi S, Qu CK, Fu H, Zhou M (2016) Discovery of dual inhibitors of MDM2 and XIAP for cancer treatment. Cancer Cell 30(4):623\u2013636","journal-title":"Cancer Cell"},{"issue":"8","key":"3339_CR104","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1039\/C6SC01167E","volume":"7","author":"DT Krist","year":"2016","unstructured":"Krist DT, Park S, Boneh GH, Rice SE, Statsyuk AV (2016) UbFluor: a mechanism-based probe for HECT E3 ligases. Chem Sci 7(8):5587\u20135595. \nhttps:\/\/doi.org\/10.1039\/C6SC01167E","journal-title":"Chem Sci"},{"key":"3339_CR105","doi-asserted-by":"crossref","unstructured":"Veggiani G, Gerpe MCR, Sidhu SS, Zhang W (2019) Emerging drug development technologies targeting ubiquitination for cancer therapeutics. Pharmacol Ther","DOI":"10.1016\/j.pharmthera.2019.03.003"},{"issue":"4","key":"3339_CR106","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1021\/ar400284t","volume":"47","author":"RM Franzini","year":"2014","unstructured":"Franzini RM, Neri D, Scheuermann J (2014) DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res 47(4):1247\u20131255. \nhttps:\/\/doi.org\/10.1021\/ar400284t","journal-title":"Acc Chem Res"},{"key":"3339_CR107","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.02.034","volume":"175","author":"D Rognan","year":"2017","unstructured":"Rognan D (2017) The impact of in silico screening in the discovery of novel and safer drug candidates. Pharmacol Ther 175:47\u201366","journal-title":"Pharmacol Ther"},{"issue":"1","key":"3339_CR108","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-017-00299-9","volume":"8","author":"Y Li","year":"2017","unstructured":"Li Y, Xie P, Lu L, Wang J, Diao L, Liu Z, Guo F, He Y, Liu Y, Huang Q, Liang H, Li D, He F (2017) An integrated bioinformatics platform for investigating the human E3 ubiquitin ligase-substrate interaction network. Nat Commun 8(1):347. \nhttps:\/\/doi.org\/10.1038\/s41467-017-00299-9","journal-title":"Nat Commun"},{"issue":"4","key":"3339_CR109","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2159-8290.Cd-11-0104","volume":"1","author":"AG Herman","year":"2011","unstructured":"Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR (2011) Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov 1(4):312\u2013325. \nhttps:\/\/doi.org\/10.1158\/2159-8290.Cd-11-0104","journal-title":"Cancer Discov"},{"issue":"8","key":"3339_CR110","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1074\/jbc.ra118.003822","volume":"294","author":"M Tian","year":"2019","unstructured":"Tian M, Zeng T, Liu M, Han S, Lin H, Lin Q, Li L, Jiang T, Li G, Lin H, Zhang T, Kang Q, Deng X, Wang H-R (2019) A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases. J Biol Chem 294(8):2880\u20132891. \nhttps:\/\/doi.org\/10.1074\/jbc.ra118.003822","journal-title":"J Biol Chem"},{"issue":"1","key":"3339_CR111","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1021\/pr300630k","volume":"12","author":"H Zhou","year":"2013","unstructured":"Zhou H, Di Palma S, Preisinger C, Peng M, Polat AN, Heck AJ, Mohammed S (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12(1):260\u2013271. \nhttps:\/\/doi.org\/10.1021\/pr300630k","journal-title":"J Proteome Res"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00018-019-03339-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-019-03339-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T23:26:26Z","timestamp":1603149986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00018-019-03339-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["3339"],"URL":"https:\/\/doi.org\/10.1007\/s00018-019-03339-3","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,21]]},"assertion":[{"value":"17 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}